Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
AGEN2373 (CD137 Agonist)
INCAGN1949 (OX40 Agonist)
Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities
Human Antibodies
August 23, 2022
,
Waight, et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Other Articles & Publications
Clinical Cancer Research
July 28, 2022
,
Bockorny B, et al.
No items found.
Balstilimab (PD-1 inhibitor)
Zalifrelimab (CTLA-4 Antagonist)
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
Other Articles & Publications
Future Oncology
July 28, 2022
,
O'Malley, et al.
No items found.
Balstilimab (PD-1 inhibitor)
Zalifrelimab (CTLA-4 Antagonist)
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
Other Articles & Publications
Journal of Clinical Oncology
July 28, 2022
,
O'Malley, et al.
No items found.